Key Drivers
- Strong Liquidity
- Persistent Losses
- Equity Deficit
AIAI Summary
CYTK is transitioning from a clinical-stage story to a MYQORZO commercial-execution bet, with non-obstructive HCM approval representing major upside but sustained revenue growth needed to outrun roughly $535M in annual cash burn, debt, and dilution risk. Investors should track quarterly MYQORZO sales, payer uptake, and cash runway before underwriting the franchise's long-term value.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Equity Deficit
CYTK has strong liquidity but remains high-risk due to persistent losses, heavy cash burn, negative equity, substantial debt, and shareholder dilution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Period-low close
- •Failed rebound
CYTK is bearish over the last month, with price at ~$68.80 support and sellers in control unless it reclaims $70.00 and then $72.10–$72.70.
Failed two-day bounce before another decline to the period low
Sentiment & News
Key News Insights:
- •Phase 3 success
- •FDA filing planned
- •Sales acceleration
Cytokinetics' strong aficamten trial results, planned FDA expansion filing, and rapidly rising Myqorzo sales support a positive growth outlook despite safety scrutiny and stock pressure.
The developments could strengthen Cytokinetics' commercial and regulatory upside, though investor focus on safety and competition remains
Similar Companies in Healthcare
Other companies in the same sector with AI ratings